{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:01Z","timestamp":1792785961635,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}]},{"name":"Tuscany Health Ecosystem","award":["ECS00000017\u2014THE"],"award-info":[{"award-number":["ECS00000017\u2014THE"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate clinical impact of ceftazidime\/avibactam on treating infections due to MDR Gram-negative bacteria in patients with haematological malignancies (HMs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, observational study at 17 Italian haematological wards that included patients with HMs receiving ceftazidime\/avibactam for the treatment of suspected or proven infections. The primary endpoint was all-cause mortality 30\u2005days after infection onset. Secondary endpoints included the development of in vitro ceftazidime\/avibactam resistance, adverse reactions and infection relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 198 patients enrolled, 66 had fever of unknown origin and 132 had microbiologically proven infections (MPIs). Enterobacterales were responsible for 98 MPIs, with KPC producers accounting for 75% of these, and carbapenem-resistant Pseudomonas aeruginosa caused 25% of MPIs. The overall 30-day mortality rate was 17.7%. Infection relapse occurred in four patients with MPI. Patients who died within 30\u2005days of infection onset tended to have pre-existing cerebrovascular diseases, a Charlson Comorbidity Index\u200a&amp;gt;\u200a4 and septic shock at infection onset and had received inadequate initial antibiotic therapy. Thirty-day mortality was independently associated with septic shock at infection onset and inappropriate initial antibiotic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study provides further evidence about the effectiveness of ceftazidime\/avibactam in treating infections in patients with HMs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae416","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:17:06Z","timestamp":1730420226000},"page":"386-398","source":"Crossref","is-referenced-by-count":17,"title":["Clinical impact of ceftazidime\/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9519-8552","authenticated-orcid":false,"given":"Mario","family":"Tumbarello","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnologies, University of Siena , Siena ,","place":["Italy"]},{"name":"Infectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria Senese , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Giuliano","sequence":"additional","affiliation":[{"name":"Infectious and Tropical Diseases Unit, Azienda Ospedaliero Universitaria Senese , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Criscuolo","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ilaria","family":"Del Principe","sequence":"additional","affiliation":[{"name":"Ematologia, Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 di Roma Tor Vergata , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u2018Ser\u00e0gnoli\u2019, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola Stefano","family":"Fracchiolla","sequence":"additional","affiliation":[{"name":"SC Ematologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Dargenio","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia e Centro Trapianti, CSE Vito Fazzi , Lecce ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiovanna","family":"Cefalo","sequence":"additional","affiliation":[{"name":"Hematology, Sant'Eugenio Hospital, ASL ROMA2 , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Nadali","sequence":"additional","affiliation":[{"name":"U.O.C. Ematologia, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale Borgo Roma , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Candoni","sequence":"additional","affiliation":[{"name":"Section of Haematology, Department of Medical and Surgical Sciences, University of Modena and Reggio , Modena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Buquicchio","sequence":"additional","affiliation":[{"name":"Ematologia con Trapianto, Ospedale Dimiccoli Barletta , Barletta ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Marchesi","sequence":"additional","affiliation":[{"name":"Haematology and Stem Cell Transplantation Unit, IRCCS Regina Elena National Cancer Institute , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Picardi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, AOU Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Lessi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology and Clinical Immunology Unit, University of Padova , Padova ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Piedimonte","sequence":"additional","affiliation":[{"name":"Hematology, \u2018Sant'Andrea\u2019 Hospital-Sapienza, University of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Prezioso","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Unit, Hospital University of Parma , Parma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piccini","sequence":"additional","affiliation":[{"name":"SOD Ematologia, Universit\u00e0 Di Firenze, AOU Careggi , Firenze ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"ASST Spedali Civili of Brescia, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[{"name":"Stem Cell Transplant Unit, AOU Citta\u2019 della Salute e della Scienza , Torino ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Buzzatti","sequence":"additional","affiliation":[{"name":"Ematologia, Dipartimento di Biomedicina e Prevenzione, Universit\u00e0 di Roma Tor Vergata , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dedola","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u2018Ser\u00e0gnoli\u2019, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum University of Bologna , Bologna ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarita","family":"Scium\u00e9","sequence":"additional","affiliation":[{"name":"SC Ematologia, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Di Renzo","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia e Centro Trapianti, CSE Vito Fazzi , Lecce ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cesini","sequence":"additional","affiliation":[{"name":"Hematology, Sant'Eugenio Hospital, ASL ROMA2 , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vatteroni","sequence":"additional","affiliation":[{"name":"U.O.C. Ematologia, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale Borgo Roma , Verona ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Raffaelli","sequence":"additional","affiliation":[{"name":"UOC Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Pagano","sequence":"additional","affiliation":[{"name":"Dipartimento Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli\u2014IRCCS , Roma ,","place":["Italy"]},{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Universit\u00e0 Cattolica del Sacro Cuore , Roma ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,15]]},"reference":[{"key":"2025020223514081700_dkae416-B1","doi-asserted-by":"publisher","first-page":"e0224465","DOI":"10.1371\/journal.pone.0224465","article-title":"Bloodstream infections caused by Escherichia coli in onco-haematological patients: risk factors and mortality in an Italian prospective survey","volume":"14","author":"Trecarichi","year":"2019","journal-title":"PLoS One"},{"key":"2025020223514081700_dkae416-B2","doi-asserted-by":"publisher","first-page":"e13186","DOI":"10.1111\/tid.13186","article-title":"Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies: results from a multicentric surveillance cohort study","volume":"21","author":"Kern","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2025020223514081700_dkae416-B3","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3389\/fmicb.2020.01422","article-title":"Infections due to carbapenem-resistant bacteria in patients with hematologic malignancies","volume":"11","author":"Lalaoui","year":"2020","journal-title":"Front Microbiol"},{"key":"2025020223514081700_dkae416-B4","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.7150\/jca.50802","article-title":"A practical update on the epidemiology and risk factors for the emergence and mortality of bloodstream infections from real-world data of 3014 hematological malignancy patients receiving chemotherapy","volume":"12","author":"Chen","year":"2021","journal-title":"J Cancer"},{"key":"2025020223514081700_dkae416-B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/21505594.2016.1213472","article-title":"Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies","volume":"8","author":"Pouch","year":"2017","journal-title":"Virulence"},{"key":"2025020223514081700_dkae416-B6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/antibiotics9020058","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam for multidrug-resistant gram negatives in patients with hematological malignancies: current experiences","volume":"9","author":"Criscuolo","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"2025020223514081700_dkae416-B7","doi-asserted-by":"publisher","first-page":"106806","DOI":"10.1016\/j.ijantimicag.2023.106806","article-title":"Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey","volume":"61","author":"Trecarichi","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223514081700_dkae416-B8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jiac.2024.01.007","article-title":"Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant Gram-negative bacteria in hematological patients: experience in a single center","volume":"30","author":"Zhen","year":"2024","journal-title":"J Infect Chemother"},{"key":"2025020223514081700_dkae416-B9","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2025020223514081700_dkae416-B10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2025020223514081700_dkae416-B11","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, Phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025020223514081700_dkae416-B12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a Phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025020223514081700_dkae416-B13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025020223514081700_dkae416-B14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025020223514081700_dkae416-B15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12879-017-2297-9","article-title":"Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem resistant Klebsiella pneumoniae bacteremias","volume":"17","author":"Micozzi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025020223514081700_dkae416-B16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1186\/s12879-021-06747-8","article-title":"Reduced mortality from KPC-K.pneumoniae bloodstream infection in high-risk patients with hematological malignancies colonized by KPC-K.pneumoniae","volume":"21","author":"Micozzi","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025020223514081700_dkae416-B17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025020223514081700_dkae416-B18","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3324\/haematol.2013.091025","article-title":"European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia","volume":"98","author":"Averbuch","year":"2013","journal-title":"Haematologica"},{"key":"2025020223514081700_dkae416-B19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2025020223514081700_dkae416-B20","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s00277-018-3535-y","article-title":"Ceftazidime-avibactam for Gram-negative multidrug-resistant bacteria in hematological patients: a single-center experience","volume":"98","author":"Metafuni","year":"2019","journal-title":"Ann Hematol"},{"key":"2025020223514081700_dkae416-B21","doi-asserted-by":"publisher","first-page":"106335","DOI":"10.1016\/j.ijantimicag.2021.106335","article-title":"The place of ceftazidime\/avibactam and ceftolozane\/tazobactam for therapy of haematological patients with febrile neutropenia","volume":"57","author":"Clerici","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223514081700_dkae416-B22","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.2147\/IDR.S374904","article-title":"Risk factors for mortality and outcomes in hematological malignancy patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infections","volume":"15","author":"Meng","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2025020223514081700_dkae416-B23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/IDR.S393802","article-title":"Benefits and safety of empiric antibiotic treatment active against KPC-K. pneumoniae in febrile neutropenic patients with acute leukemia who are colonized with KPC-K. pneumoniae. A 7-years retrospective observational cohort study","volume":"16","author":"Micozzi","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2025020223514081700_dkae416-B24","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.2147\/IDR.S419064","article-title":"Clinical characteristics and prognosis of bloodstream infection with carbapenem-resistant Pseudomonas aeruginosa in patients with hematologic malignancies","volume":"16","author":"Yuan","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2025020223514081700_dkae416-B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12941-023-00586-y","article-title":"Bloodstream infections due to carbapenem-resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options","volume":"22","author":"Zhang","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2025020223514081700_dkae416-B26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s15010-022-01876-x","article-title":"Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections","volume":"50","author":"Zhen","year":"2022","journal-title":"Infection"},{"key":"2025020223514081700_dkae416-B27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/microorganisms12010195","article-title":"Ceftazidime-avibactam improves outcomes in high-risk neutropenic patients with Klebsiella pneumoniae carbapenemase-producing enterobacterales bacteremia","volume":"12","author":"Herrera","year":"2024","journal-title":"Microorganisms"},{"key":"2025020223514081700_dkae416-B28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2025020223514081700_dkae416-B29","doi-asserted-by":"publisher","first-page":"e00883-17","DOI":"10.1128\/AAC.00883-17","article-title":"Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223514081700_dkae416-B30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025020223514081700_dkae416-B31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/cid\/ciy492","article-title":"Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"68","author":"Tumbarello","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025020223514081700_dkae416-B32","doi-asserted-by":"publisher","first-page":"ofz522","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime-avibactam for multidrug-resistant Gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2025020223514081700_dkae416-B33","doi-asserted-by":"publisher","first-page":"e02320-19","DOI":"10.1128\/AAC.02320-19","article-title":"Ceftazidime-avibactam to treat life-threatening infections by carbapenem-resistant pathogens in critically ill mechanically ventilated patients","volume":"64","author":"Tsolaki","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223514081700_dkae416-B34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10096-014-2233-5","article-title":"Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients","volume":"34","author":"Freire","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025020223514081700_dkae416-B35","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1002\/ajh","article-title":"Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey","volume":"91","author":"Trecarichi","year":"2016","journal-title":"Am J Hematol"},{"key":"2025020223514081700_dkae416-B36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jinf.2016.07.002","article-title":"Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies","volume":"73","author":"Satlin","year":"2016","journal-title":"J Infect"},{"key":"2025020223514081700_dkae416-B37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijantimicag.2016.01.011","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases","volume":"47","author":"Tofas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223514081700_dkae416-B38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40121-020-00288-4","article-title":"Evaluation of the INCREMENT-CPE, Pitt bacteremia and qPitt scores in patients with carbapenem-resistant Enterobacteriaceae infections treated with ceftazidime-avibactam","volume":"9","author":"Jorgensen","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2025020223514081700_dkae416-B39","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025020223514081700_dkae416-B40","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dkaa503","article-title":"Ceftazidime\/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study","volume":"76","author":"Karaiskos","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025020223514081700_dkae416-B41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-023-00762-9","article-title":"The use and effectiveness of ceftazidime-avibactam in real-world clinical practice: EZTEAM study","volume":"12","author":"Soriano","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2025020223514081700_dkae416-B42"},{"key":"2025020223514081700_dkae416-B43","doi-asserted-by":"publisher","first-page":"e02497-17","DOI":"10.1128\/AAC.02497-17","article-title":"Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223514081700_dkae416-B44","doi-asserted-by":"publisher","first-page":"106075","DOI":"10.1016\/j.ijantimicag.2020.106075","article-title":"Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort","volume":"56","author":"Cast\u00f3n","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223514081700_dkae416-B45","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40268-018-0241-0","article-title":"Population pharmacokinetic modelling of ceftazidime and avibactam in the plasma and epithelial lining fluid of healthy volunteers","volume":"18","author":"Dimelow","year":"2018","journal-title":"Drugs R D"},{"key":"2025020223514081700_dkae416-B46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijantimicag.2019.08.025","article-title":"Efficacy of ceftazidime\/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: a meta-analysis","volume":"54","author":"Onorato","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025020223514081700_dkae416-B47","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.ajt.2023.03.011","article-title":"Efficacy of ceftazidime-avibactam in solid organ transplant recipients with bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae","volume":"23","author":"P\u00e9rez-Nadales","year":"2023","journal-title":"Am J Transplant"},{"key":"2025020223514081700_dkae416-B48","doi-asserted-by":"publisher","first-page":"e02097-16","DOI":"10.1128\/AAC.02097-16","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223514081700_dkae416-B49","doi-asserted-by":"publisher","first-page":"e02534-16","DOI":"10.1128\/AAC.02534-16","article-title":"Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum \u03b2-lactamases","volume":"61","author":"Haidar","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223514081700_dkae416-B50","doi-asserted-by":"publisher","first-page":"ciae332","DOI":"10.1093\/cid\/ciae332","article-title":"Rates of resistance to ceftazidime-avibactam and ceftolozane-tazobactam among patients treated for multidrug-resistant Pseudomonas aeruginosa bacteremia or pneumonia","volume":"21","author":"Shah","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/386\/60683452\/dkae416.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/386\/60683452\/dkae416.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T18:51:54Z","timestamp":1738522314000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/2\/386\/7901078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,11,15]]},"published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae416","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,11,15]]}}}